(Mailing list information, including instructions, is located at the end of this message.)
Dyax Corp. (DYAX)
Attacks of swelling can become more severe in late childhood and adolescence.
DYAX reported that the U.S. FDA has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older.
With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and older. KALBITOR, which was discovered and developed by DYAX , is also the only therapy that is not purified from human plasma that has been approved to treat this patient group.
DYAX is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. DYAX currently markets KALBITOR for the treatment of acute attacks of HAE in patients 12 years of age and older. DYAX is also developing DX-2930 for the prophylactic treatment of HAE.
More about Dyax Corp. (DYAX) at www.pennyomega.com/disclaimer